Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti- inflammatory product candidates targeting SH2-containing inositol-5'- phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, rosiptor (AQX-1125), is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September, 2016, we began enrolling patients in a Phase 3 clinical trial in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Aquinox is publicly traded on NASDAQ (AQXP) with offices in Vancouver, BC, Canada and in San Bruno, CA, USA.
The Scientist, Clinical Research, will play a key role on our growing Clinical Research team. Reporting to the Senior Director, Clinical Development and Product Planning, this role will provide scientific and clinical research contributions to support our expanding Clinical Development programs. This position may be located in our office in either Vancouver, BC, Canada or San Bruno, CA, USA.
The Scientist, Clinical Research will:
What you bring:
Our current clinical trials, exceptional team, and strong track record make it an excellent time to seize this exciting opportunity! We provide a collaborative and innovative environment with competitive incentive packages and rewards. Moreover, we provide the opportunity to partake in meaningful work.
Interested candidates are invited to forward their resume and cover letter to *******@*********.com, indicating why you feel you are a fit for the Scientist, Clinical Research role at Aquinox Pharmaceuticals, Inc.
We thank all applicants for their interest; only those chosen for an interview will be contacted.